PharmaFacts for Case Managers July 2025
Yeztugo • Generic Name: Lenacapavir • Company: Gilead Sciences, Inc. • Treatment For: Pre-exposure prophylaxis of HIV to reduce the risk of getting HIV-1 in adults and adolescents. • Description: A human immunodeficiency virus type 1 (HIV1) capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1. • Drug Class: Selective HIV-1 capsid inhibitors. • Dosing Information: Tablets for oral use (300 mg), injection for subcutaneous use in a single-dose vial (463.5 mg/1.5 mL). The initial dose consists of 2 Yeztugo injections (Day 1) and 2 Yeztugo tablets (Days 1 and 2). After completing the initial dose, 2 Yeztugo injections every 6 months. Black Box Warning Risk of drug resistance with use of Yeztugo for HIV-1 pre-exposure prophylaxis in undiagnosed HIV-1 infection. Individuals must be tested for HIV-A before initiating Yeztugo and before each subsequent injection. • Side Effects: Injection site reaction, headache, and nausea.
• Full Prescribing Information: https://www.gilead.com/-/ media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.pdf
Zusduri • Generic Name: Mitomycin • Company: UroGen Pharma Ltd. • Treatment For: Low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC), in adults who have previously received bladder surgery to remove the tumor, and it did not work or is no longer working. • Description: A sustained-release, hydrogel-based formulation of mitomycin for intravesical treatment of LG-IR-NMIBC.
Brought to you by the publishers of CareManagement
• Dosing Information: Zusduri is administered by intravesical instillation only. Recommended dose is 75 mg (56 mL) instilled once weekly for six weeks into the bladder via urinary catheter. • Side Effects: The most common side effects, including laboratory abnormalities, that occurred in patients were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. • Full Prescribing Information: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2025/215793s000lbl.pdf
Widaplik • Generic Name: Telmisartan, Amlodipine, and Indapamide • Company: George Medicines • Treatment For: Hypertension in adult patients to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. • Description: Widaplik is a fixed-dose combination tablet of an angiotensin II (telmisartan), a calcium channel blocker (amlodipine), and a diuretic (indapamide). • Dosing Information: Widaplik is available in three fixeddose combinations: 10 mg telmisartan/1.25 mg amlodipine, 0.625 mg indapamide; 20 mg telmisartan/2.5 mg amlodipine/1.25 indapamide; 40 mg telmisartan/5 mg amlodipine/ 2.5 mg indapamide. Initial treatment of hypertension: start with Widaplik (10 mg/ 1.25 mg/0.625 mg) or Widaplik (20 mg/2.5 mg/1.25 mg) once daily. Initial treatment for elderly patients: start with Widaplik (10 mg/1.25 mg/0.625 mg) Titrate dose: Adjust dose based on clinical response at intervals of approximately 2 weeks. Maximum dose: Widaplik 40 mg/5 mg/2.5 mg orally once daily. • Side Effects: Dizziness, headache, fatigue, nausea, hypotension, cough.
• Drug Class: Antibiotic/antineoplastic. PharmaFacts | July 2025 1